Accessibility Menu
Biogen logo

Biogen(NASDAQ) BIIB

Market Cap$32.62BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1991)+7,673%
5 Year-36%
1 Year+62%
1 Month+10%
Premium Feature
Moneyball Superscore
64/100
$221.20
+0.20%
+0.43Today
After hours$221.15-$0.05 (-0.02%)
Biogen last closing stock price
MetricPriceDate
Last closeUSD 221.072026-08-26
Biogen stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-0.22%USD 221.562026-08-19
1 month+10.46%USD 200.142026-07-27
3 month+12.57%USD 196.392026-05-28
Year to date+25.62%USD 175.992025-12-31
1 year+61.7%USD 136.722025-08-26
3 year-16.4%USD 264.432023-08-25
5 year-35.58%USD 343.192021-08-27
Since inception+7,673.42%USD 2.841991-09-17

Biogen Financials at a Glance

Market Cap

$32.62BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$9.95B

Net Income (TTM)

$835.09M

EPS (TTM)

$5.65

P/E Ratio

39.10

Dividend

$0.00

Beta (Volatility)

0.70 (Low)

Price

$221.20

Volume

647,334.324

Open

$219.34

Previous Close

$221.07

Daily Range

$218.69 - $222.00

52-Week Range

$131.52 - $222.85

Estimated Earnings Date

Oct 29, 2026

BIIB News

Doctor holding clipboard stands with virtual DNA double helix in the air near him.

7 Best Genomics Stocks for 2026 and How to Invest

Lyle DalyAug 17, 2026
Person in a lab gazing into a microscope

Why Biogen Stock Topped the Market Today

Eric VolkmanJul 29, 2026
adaptimmune

Best Healthcare Stocks to Buy in 2026

James HalleyMay 14, 2026
Two people participating in a telehealth session

Why Biogen Stock Was a Winner on Wednesday

Eric VolkmanApr 29, 2026
nurse checking elderly patients blood pressure long term care senior nursing home POC

This Healthcare Stock Has Made Long-Term Investors Rich -- Can It Keep Doing It?

Prosper Junior BakinyApr 16, 2026
Healthcare professional inspecting charts

Why Biogen Stock Got Mashed on Monday

Eric VolkmanApr 6, 2026
Person checking medicine on a shelf in a pharmacy

Why Biogen Stock Sank While the Market Soared on Thursday

Eric VolkmanMar 31, 2026
Biotech scientist working on a tablet with bio-related icons projected above it.

How to Invest in VanEck Biotech ETF (BBH)

Tony DongFeb 25, 2026
Page 1

BIIB: Motley Fool Moneyball Superscore

64

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Biogen

Biogen Inc. makes medicines for people with brain and nervous system diseases. These treatments help patients manage conditions like multiple sclerosis and Alzheimer's disease. The company also creates drugs for rare blood and kidney disorders.

What Does Biogen Sell?

  • Multiple Sclerosis: Therapies like TYSABRI and TECFIDERA used to treat nerve damage; accounted for 50.2% of product revenue, net in the second quarter of 2026.
  • Rare Disease: Medications such as SPINRAZA and SKYCLARYS for genetic conditions; represented 31.4% of product revenue, net in the second quarter of 2026.
  • Specialized Immunology: Newly acquired treatments for vision loss and blood disorders; made up 6.7% of product revenue, net in the second quarter of 2026.
  • Collaborative Therapies: Partnerships for cancer and autoimmune treatments like OCREVUS that generate royalty and profit-sharing income.
  • Biosimilars: Lower-cost versions of existing drugs for inflammatory conditions; accounted for 8.0% of product revenue, net in the second quarter of 2026.

Buying Into New Markets

  • Acquired Apellis Pharmaceuticals in May 2026 to add treatments for vision loss and rare blood disorders.
  • Purchased exclusive rights to felzartamab in China from TJ Biopharma in April 2026.
  • Entered a license agreement with Alteogen Inc. in March 2026 to develop new medicine delivery technology.
  • Agreed to acquire RayThera Inc. in June 2026 to expand into treatments for inflammatory conditions.

Global Production and Partnerships

Biogen operates a large-scale manufacturing plant in Switzerland and continues to modernize facilities in North Carolina. The company shares the financial risks of drug development through long-term partnerships with major pharmaceutical firms.

The Latest Financial Facts

  • Total revenue was $2.7 billion in the second quarter of 2026, up 3.4% year over year.
  • Product revenue, net reached $1.9 billion in the second quarter of 2026, up 2.0% year over year.
  • Net cash flow from operations was $1.1 billion for the six-month period ended June 30, 2026.
  • Cash, cash equivalents, and marketable securities totaled $1.3 billion as of June 30, 2026.

Evolution of the Business

Biogen has evolved from a heavy focus on multiple sclerosis toward a broader portfolio including rare diseases and immunology. This evolution relies on acquisitions and new product launches to replace revenue from older drugs facing generic competition.

AI Generated • Jul 29, 2026

Industry

Biotechnology

Sector

Health Care

Employees

7,500

CEO

Christopher A. Viehbacher, CPA

Website

www.biogen.com

Headquarters

Cambridge, MA 02142, US

BIIB Financials

Key Financial Metrics (TTM)

Gross Margin

67.71%

Operating Margin

12.79%

Net Income Margin

8.39%

Return on Equity

4.52%

Return on Capital

7.45%

Return on Assets

2.60%

Earnings Yield

2.56%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$32.62BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

147.75M

Volume

647.33K

Avg. Volume

1.15M

Financials (TTM)

Gross Profit

$6.74B

Operating Income

$1.27B

EBITDA

$1.67B

Operating Cash Flow

$2.88B

Capital Expenditure

$89.80M

Free Cash Flow

$2.97B

Cash & ST Invst.

$1.29B

Total Debt

$8.36B

Biogen Performance Analysis

Biogen annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 9,433,400,000-9.3%
20232023-12-31USD 9,417,000,000-0.2%
20242024-12-31USD 9,266,600,000-1.6%
20252025-12-31USD 9,533,100,0002.9%
Biogen sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-7.2%
Q42025-12-31-7.1%
Q12026-03-318.7%
Q22026-06-3010.4%
Biogen annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 20.87100.6%
20232023-12-31USD 7.97-61.8%
20242024-12-31USD 11.1940.3%
20252025-12-31USD 8.79-21.4%
Biogen sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-27.1%
Q42025-12-31-110.4%
Q12026-03-31751.5%
Q22026-06-30-69.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$2.74B

+3.4%

Gross Profit

$1.56B

-8.4%

Gross Margin

56.92%

N/A

Market Cap

$32.62BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$4.35M

N/A

Employees

7,500

N/A

Net Income

$97.50M

-84.6%

EBITDA

$78.20M

-93.0%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$1.29B

-53.4%

Total Debt

$8.36B

+26.7%

Accounts Receivable

$1.89B

-9.5%

Inventory

$2.38B

+4.8%

Long Term Debt

$7.56B

+14.6%

Short Term Debt

$800.00M

N/A

Return on Assets

2.60%

N/A

Return on Invested Capital

4.52%

N/A

Free Cash Flow

$489.80M

+239.4%

Operating Cash Flow

$448.90M

+179.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
DXCMDexCom, Inc.
$88.96-0.22%
WATWaters Corporation
$414.17-0.07%
LHLabcorp Holdings Inc.
$335.72-0.58%
DGXQuest Diagnostics Incorporated
$245.00+0.20%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$209.66-0.02%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.87-0.02%
BITOProShares Trust - ProShares Bitcoin ETF
$10.58-0.01%
INTCIntel
$88.24+0.01%

Questions About BIIB

What is the current price of Biogen?

Biogen is trading at $221.07 per share.

What is the 52-week range for Biogen?

Over the past 52 weeks, Biogen has traded between $131.52 and $222.85.

How much debt does Biogen have?

As of the most recent reporting period, Biogen reported total debt of $8.36B.

How much cash does Biogen have on hand?

Biogen reported $1.29B in cash and cash equivalents in its most recent financial results.

What is Biogen’s dividend yield?

Biogen does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services